Edgewise Therapeutics, Inc.
EWTX
Kedudukan dalam Saham
#3981
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Harga Saham
$38.12
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$4.10B
Perubahan (1 hari)
2.50%
Perubahan (1 tahun)
147.69%
Negara
US
Perdagangan Edgewise Therapeutics, Inc. (EWTX)
Kategori
Healthcare
Bilangan saham terbitan bagi Edgewise Therapeutics, Inc. (EWTX)
Bilangan saham terbitan setakat June 2026: 107.67M
Menurut laporan kewangan terkini dan harga saham Edgewise Therapeutics, Inc., bilangan saham terbitan semasa ialah 107.67M. Pada akhir December 2023, syarikat mempunyai 63.72M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Edgewise Therapeutics, Inc. (EWTX) dari 2019 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 107.67M | 16.51% |
| 2024 | 92.41M | 45.02% |
| 2023 | 63.72M | 18.90% |
| 2022 | 53.59M | 8.27% |
| 2021 | 49.50M | 0.58% |
| 2020 | 49.22M | 0.00% |
| 2019 | 49.22M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 135.81% |
US
|
|
| 396.00M | 267.79% |
US
|
|
| 478.91M | 344.80% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -42.24% |
NL
|
